919-206-7900
Polarean Imaging plc.'s technology is for research use only

Corporate News

Grant of Share Options

23 May 2019

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that upon the recommendation of the Company's Remuneration Committee it has granted options over a total of 1,200,000 ordinary shares of 0.00037p each in the Company ("Ordinary Shares") to Chuck Osborne, Chief Financial Officer (the "Options").

The exercise price for the Options is 15 pence and 25% of the Options shall vest on 29 April 2020, whilst the remaining 75% of the Options shall vest in equal portions on the last day of each calendar month over the period of 36 months, starting on 31 May 2020.

Following the grant of the Options referred to above, there are 22,394,131 outstanding options and warrants over Polarean's Ordinary Shares, representing 18% of the Company's Ordinary Shares and total voting rights on a fully diluted basis.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

Enquiries:

Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
 
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 /
+44 (0)7879 741 001

 

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimise the imaging of 129Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 1 Details of the person discharging managerial responsibilities / person closely associated
a) Names Charles F Osborne Jr
2 Reason for the notification
a) Position/status CFO (Non-Board)
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a) Name Polarean Imaging Plc ("Polarean")
b) LEI 213800DGR2BHXJ36OL37
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Options over Polarean's ordinary shares of £0.0037p each (the "Options")
b) Identification code  GB00BF3DT583
c) Nature of the transaction  Grant of Options  
d) Price and volumes Exercise Price - 15p per Option
Volume of Options: 1,200,000
d) Aggregated information
- Aggregated volume
- Price
 Volume: 1,200,000 Options
Price: Each Option has an exercise price of 15p
e) Date of the transaction  23 May 2019
f) Place of the transaction London Stock Exchange, AIM Market

 

« back to Corporate News